Supplemental Table 2: Non-severe, severe and rare adverse events for the 9-month baseline (Period 1) and 12-month study intervention period (Period 3).

Adverse Events			
	Period 1 (n=158)	**Period 3 (n=216)**	**p Value**
Non-Severe Adverse Events, n (%)	48 (30)	98 (45)	<0.01
Bradycardia <100 bpm	12 (8)	7 (3)	0.06
Tachycardia >180 bpm	0 (0)	10 (5)	<0.01
Desaturation <88% SpO2	10 (6)	65 (30)	<0.01
Esophageal intubation with immediate identification	7 (4)	4 (2)	0.15
Oral or airway bleeding	6 (4)	5 (2)	0.40
Difficult bag-mask ventilation	8 (5)	3 (1)	0.04
Emesis	5 (3)	4 (2)	0.41
Severe Adverse Events, n (%)	30 (19)	40 (19)	0.91
Severe bradycardia <60 bpm	2 (1)	3 (1)	0.92
Severe desaturation >20% from SpO2 baseline	3 (2)	28 (13)	<0.01
Esophageal intubation with delayed identification	1 (1)	1 (1)	0.82
Chest wall rigidity	7 (4)	6 (3)	0.39
Direct airway trauma	13 (8)	0 (0)	<0.01
Transition to emergent	4 (3)	2 (1)	0.22
Rare Adverse Events, n (%)	1 (0)	1 (0)	0.82
Hypotension requiring intervention	0 (0)	0 (0)	–
Chest compressions	0 (0)	1 (100)	0.39
Code medications	0 (0)	0 (0)	–
Pneumothorax	1 (100)	0 (0)	0.24
Death	0 (0)	0 (0)	–
Procedural Events, n (%)	19 (12)	30 (14)	0.60
Unable to extubate if planned	5 (3)	10 (5)	0.48
Tube dislodged before/during taping requiring additional attempt	4 (3)	9 (4)	0.39
Pain/agitation requiring additional medications	6 (4)	9 (4)	0.86
Equipment failure	0 (0)	2 (1)	0.23
Needed equipment not at bedside	4 (3)	0 (0)	0.02

Abbreviations: BPM, Beats Per Minute; SpO2, Oxygen Saturation